2024 Radionuclide Theranostics for the Management of Cancer Gordon Research Conference and Gordon Research Seminar

Project Summary/Abstract The Gordon Research Conference (GRC) and Symposium (GRS) for "Radionuclide Theranostics for the Management of Cancer", a rapidly emerging field in diagnostic and therapeutic oncology, will be held July 6- 12, 2024. The scientific goal of this meeting will be to address the challenges and advancements of

radionuclide theranostics in the field of cancer. The inaugural GRS component will target the preclinical sciences whereas the GRC component will target the clinically translated science with ample time for discussions. Our aim is to create the hybrid space for radioimmunobiology in cancer and attract a significant

number of attendees (250) including scientists, students, and physicians from academia and companies developing Radionuclide Theranostics for a viable conference and creating the future community. The unique format of GRC and GRS allowing participation by application and encouragement to share unpublished data

with fostering discussions within and between sessions creates the opportunity for formal and informal interactions and collaborations that are likely to have significant and sustained impact on the field. We are witnessing a fundamental transformation and unprecedented growth to offer precise antitumoral therapies and

diagnostics while increasing the awareness on quality of life with minimized toxicity and side effect profile. Today, there are more than 100 pharmaceutical companies, over 250 active clinical trials using beta, alpha or gamma emitting radionuclides that are supported by not only private but national laboratories and DOE

(department of energy). As clearly seen, the field of Radionuclide Theranostics depends on collaboration between academia, federal and private organizations with the mutual aim of achieving improved patient outcomes. Funds from the NIH R13 conference grant will be specifically targeted to promote participation in the

conference by women, under-represented minorities, people with disabilities and particularly graduate students, postdoctoral fellows, and early career investigators.